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Compassionate use of new drugs in
children and adolescents with
multidrug-resistant and extensively
drug-resistant tuberculosis: early
experiences and challenges
To the Editor:
The World Health Organization (WHO) estimated that 480000 new multidrug-resistant (MDR) tuberculosis
(TB) cases occurred globally in 2014, with 190000 deaths. Limited data are available on the burden of
MDR-TB in children. A recent systematic review estimated that 32000 children acquire MDR-TB annually;
of these, very few are correctly diagnosed and provided with appropriate treatment [1].
Treatment of drug-resistant TB is long, expensive and associated with frequent adverse events [1–5]. In
children, treatment is further complicated by limited data on appropriate dosing and safety, and a lack of
child-friendly formulations. New anti-TB drugs are urgently needed to improve treatment tolerability and
outcome, particularly for MDR-TB cases with additional second-line drug resistance, for whom identifying
at least four active drugs is difficult with the current armamentarium of drugs [1, 4–11]. Two novel
anti-TB drugs, delamanid [6, 8, 12] and bedaquiline [6, 7, 9, 10, 12], have received conditional approval
for use in adults with MDR-TB. While the WHO interim guidance does not include a recommendation
on their use in children due to lack of data, the Centers for Disease Control and Prevention guidelines
state that bedaquiline use can be considered for children when treatment options are limited.
A number of paediatric clinical trials are ongoing or planned. The Otsuka 232 (phase 1, pharmacokinetics
and safety to determine the appropriate dose for MDR-TB in children) and 233 (phase 2, 6-month safety,
efficacy and pharmacokinetics trial in children with MDR-TB) trials of delamanid have begun recruitment.
Preliminary pharmacokinetics and safety data in 6–17-year-old children from these trials have been
presented, showing an excellent safety profile and leading to weight-based dosing recommendations for
patients of 20–35 kg to receive half the adult dose (50 mg of delamanid twice daily) (presented in poster
format (A-960) by J. Hafkin; Pharmacokinetics and safety of delamanid in paediatric MDR-TB patients,
ages 6–17 years; San Diego, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC),
2015). A follow-up study to confirm the long-term safety, tolerability and pharmacokinetics of delamanid
in these age groups and younger children (0–5 years) is ongoing and data are not yet available (presented in
poster format (EP-115-04) by J. Hafkin; Long-term safety, tolerability and pharmacokinetics of delamanid
in paediatric MDR-TB patients, ages 12–17 years; Cape Town, The 46th Union World Conference on Lung
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Health, 2015). Neither the Janssen C21 trial of bedaquiline (phase 2, pharmacokinetics, tolerability and
anti-mycobacterial activity in children with MDR-TB) nor the US National Institutes of Health
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network planned trial of
bedaquiline pharmacokinetics and safety in HIV-infected and uninfected children, have yet begun enrolling.
The Janssen bedaquiline compassionate use programme excluded all subjects aged <18 years, while
delamanid is available to children from 12 years of age, and recently from 6 years, through the Otsuka
compassionate use programme. Each request for delamanid compassionate use submitted to Otsuka is
reviewed by an independent panel of experts, to assess the appropriateness and safety of delamanid use
before the drug is provided. The aim of this report is to share the initial experience and challenges of
compassionate use of delamanid in children and adolescents at a global level. The information reported
here was collected through the two bodies providing independent advice on the rational use of new drugs:
the TB Consilium (www.tbconsilium.org) [8] and the endTB committee (Médecins Sans Frontières (MSF),
Partners in Health, and Interactive Research and Development; www.endtb.org).
Between February 2014 and March 2016, Otsuka received 19 requests for delamanid compassionate use
for paediatric patients aged <18 years. All requests were considered appropriate by both the external
committees and Otsuka, and hence were enrolled in the delamanid compassionate use programme.
Requests were received from Italy (n=1), South Africa (n=5), Georgia (MSF settings; n=4), India (n=5;
four from MSF settings), Namibia (n=1), Swaziland, Russia and Armenia (MSF settings; one case each).
Data from patients are summarised in table 1.
The rationale for delamanid requests was mainly the limited treatment options due to extensive resistance
pattern or poor response to second-line anti-TB treatment, although in one case it was for reinforcement
of the treatment regimen in a patient with adverse events. The TB Consilium and endTB committee
experts recommended the use of delamanid as the best treatment option in these patients.
All 19 paediatric cases enrolled in the delamanid compassionate use programme had bacteriologically
confirmed pulmonary MDR- or extensively drug-resistant (XDR)-TB (two cases also had extrapulmonary
TB). Drug susceptibility testing confirmed resistance to four to 15 anti-TB drugs. Only three patients
(patients 5, 6 and 19 in table 1) were HIV positive.
Out of 19 enrolled patients, 16 (84%) have already started treatment with delamanid. The mean age at
treatment initiation was 14.4 years (range 8–17 years). All cases received delamanid 100 mg twice daily
(adult dosage), except one who received 50 mg twice daily due to a body weight of 22 kg. Of these, six
patients have already completed 24 weeks of delamanid, while 10 are still receiving the delamanid.
All patients showed good tolerability to delamanid with no or mild adverse events, except one patient
from India. This patient was receiving a combination of delamanid-capreomycin-ethionamide-cycloserine-
clofazimine-imipenem-amoxicillin/clavulanate-pyrazinamide, and experienced severe vomiting, renal
impairment and severe electrolyte disturbances (hypokalaemia and hypomagnesaemia) that led to QTcF
(QT interval in the ECG corrected according to Fredericia formula) prolongation (>500 ms) requiring
temporary delamanid discontinuation (albumin was normal). After management of vomiting and
electrolyte imbalance correction, the patient was able to complete delamanid treatment without further
QTcF prolongation.
As shown in table 1, the interim treatment response is good: 13 (81.2%) out of 16 were Mycobacterium
tuberculosis culture-negative at the time of this report (three patients were recently started on delamanid,
so the interim treatment responses are not yet available). Except for one patient who has successfully
completed MDR-TB treatment, the remaining patients are continuing treatment and do not have final
treatment outcomes yet.
The combination of delamanid and bedaquiline has been limited due to concerns regarding the QT
prolongation effects of both drugs. However, there are initial experiences with their simultaneous use in
adults (now also possible through compassionate use) [13, 14]. This combination could be considered in
children in the absence of effective alternative treatment options [4, 5], under enhanced clinical
monitoring [12–15].
Globally, there are very few children who have access to delamanid compared with the likely number who
could benefit from it. Healthcare providers have described a number of challenges to the access of
delamanid. The compassionate use mechanism, despite efforts to facilitate quick access, is a long, multistep
and time-demanding process (request, permission for importation/use, informed consent, health staff
training on the compassionate use protocol, reporting requirements and importation). This can result in
substantial delays in treatment initiation, which could adversely affect treatment outcome. In our study,
the median delay between process initiation and delamanid initiation was 73.5 days (range 14–153 days).
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TABLE 1 Paediatric cases enrolled in Otsuka delamanid compassionate use programme, from February 2014 to March 2016
Patient Country
of origin
Age
years
Sex TB form Test results at time of
delamanid request
Resistance profile Expert panel consulted and
indication for delamanid
Drugs used prior to
delamanid
Started
delamanid
Treatment outcome or
interim treatment response
1 Italy 13 M P and EP SS+/C+ (MGIT), Xpert+ XDR-TB: H, R, Z, E, S,
Rfb, Amk, Cm, Km,
Lfx, Mfx, Ofx, Eto, Pto,
HdH
TB Consilium: extensive
resistance to SLDs, drug
toxicity and limited options for
treatment
H, Z, E, Amk, Mfx, Eto,
PAS, Tzd, Amx/Clv, Clr,
Cfz, Lzd, Mpm
Yes Cured
2 South
Africa
17 F P SS+/C+, Xpert+ XDR-TB: H, R, Amk,
Km, Ofx, Eto
TB Consilium: extensive
resistance to SLDs and severe
clinical presentation
H, Z, E, Cm, Km, Mfx,
Eto, PAS, Tzd, Cfz, HdH
No#
3 South
Africa
13 M P SS+/C+, Xpert+ XDR-TB: H, R, Amk,
Ofx
TB Consilium: extensive
resistance to SLDs and severe
clinical presentation
Z, E, Cm, Km, Mfx, Eto,
PAS, Tzd, Amx/Clv, Clr,
Cfz, Lzd
Yes Currently culture negative,
good clinical response,
delamanid completed
4 South
Africa
13 F P SS−/C+ (MGIT), Xpert+ XDR-TB: H, R, Amk,
Ofx
TB Consilium: extensive
resistance to SLDs and severe
clinical presentation
E, Z, Cm, Mfx, Eto, PAS,
Tzd, Cfz, HdH, Lzd
Yes Currently culture negative,
good clinical response,
delamanid ongoing
5 South
Africa
8 M P SS+/C+ (MGIT), Xpert
MTB+, R resistant
Pre-XDR: H, R, Amk,
Cm, Km, Eto
TB Consilium: extensive
resistance to SLDs and severe
clinical presentation
Z, Amk, Mfx, Eto, Tzd Yes First culture not yet
available
6 Namibia 9 M P and EP SS−/C−, lymph C+
(MGIT)
XDR-TB: H, R, E, S,
Amk, Cm, Km, Lfx,
Mfx, Ofx, Eto, PAS,
Cs, HdH
TB Consilium: extensive
resistance to SLDs and severe
clinical presentation
Z, Cm, Mfx, PAS, Cs,
Amx/Clv, Clr, Cfz, HdH
No¶
7 South
Africa
12 F P SS−/C+ (MGIT), Xpert
indeterminate
XDR-TB: H, R, S,
Amk, Cm, Km, Ofx,
Eto, Pto, HdH
TB Consilium: extensive
resistance to SLDs and severe
clinical presentation
H, R, Z, E, Eto, Tzd, Lfx Yes Currently culture negative,
good clinical response,
delamanid ongoing
8 India 12 F P SS+/C+ (MGIT) XDR-TB: R, H, Z, E, S,
Amk, Cm, Km, Mfx,
Ofx, Eto, PAS, Cs, Lzd
TB Consilium: extensive
resistance to SLDs and severe
clinical presentation
E, Z, Cm, Mfx, PAS, Cs,
Amx/Clv, Clr, Cfz, Lzd,
Mpm
Yes First culture not yet
available
9 India 17 F P SS+/C+ (MGIT) XDR-TB: H, R, E, S,
Amk, Cm, Km, Mfx,
Ofx, Eto, PAS
endTB committee: extensive
resistance to SLDs
H, R, Z, E, S, Km, Mfx,
Pto, PAS, Cs, Amx/Clv,
Clr, Cfz, Lzd
Yes Currently culture negative,
good clinical response,
delamanid completed
10 India 15 F P SS+/C+ (MGIT) XDR-TB: H, R, E, S,
Amk, Km, Ofx, Eto,
PAS, Cfz
endTB committee: extensive
resistance to SLDs
H, R, Z, E, Km, Mfx, Eto,
PAS, Cfz, Lzd
Yes Currently culture negative,
good clinical response,
delamanid completed
11 India 16 M P SS−/C+ (MGIT) XDR-TB: H, R, E, S,
Amk, Cm, Km, Mfx,
Ofx, Eto, PAS
endTB committee: failure of
previous treatment and
extensive resistance to SLDs
H, R, Z, E, Rfb, Cm, Km,
Lfx, Mfx, Eto, PAS, Cs,
Amx/Clv, Cfz, HdH, Lzd
Yes Culture negative, good
clinical response,
delamanid completed
12 India 13 F P and EP
(lymph
node)
SS+/C+ (MGIT), Xpert
MTB+, R resistant
XDR-TB: H, R, E, Z, S,
Amk, Cm, Km, Mfx,
Ofx, Eto, PAS, Cs
endTB committee: extensive
resistance to SLDs
H, R, Z, E No+
13 Georgia 16 M P SS+/C+ (MGIT), Xpert
MTB+, R resistant
MDR-TB: H, R, E, Z endTB committee: no
improvement with SLDs (still
smear positive after 3 months
of treatment)
E, Z, Cm, Mfx, Cs, PAS,
Lzd
Yes Currently culture negative,
good clinical response,
delamanid ongoing
Continued
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TABLE 1 Continued
Patient Country
of origin
Age
years
Sex TB form Test results at time of
delamanid request
Resistance profile Expert panel consulted and
indication for delamanid
Drugs used prior to
delamanid
Started
delamanid
Treatment outcome or
interim treatment response
14 Georgia 17 M P SS−/C+ (MGIT), Xpert
MTB+, R resistant
Pre-XDR (FQ): H, R, E,
S, Ofx
endTB committee: no
improvement with SLDs
(culture positive after 7 months
of treatment, progression of
infiltrates and cavities)
H, Z, E, Cm, Lfx, Mfx,
Pto, PAS, Cs
Yes Culture negative, good
clinical response,
delamanid ongoing
15 Georgia 15 M P SS−/C+ (MGIT), HAIN
MTB+, R resistant
XDR-TB: H, R, E, S,
Km, Ofx
endTB committee: extensive
resistance to SLDs and severe
clinical presentation (bilateral
lesions)
H, R, Z, E, Cm, Lfx, Mfx,
Pto, PAS, Cs, Cfz, Lzd
Yes Culture negative, good
clinical response,
delamanid completed
16 Georgia 17 M P SS+/C+ (MGIT), Xpert
MTB+, R resistant
Pre-XDR (FQ): H, R, E,
S, Ofx
endTB committee: no clinical or
radiological improvement with
SLDs
E, Z, Cm, Lfx, Mfx, Pto,
PAS, Cs, Amx/Clv, Clr,
Cfz
Yes Culture negative, good
clinical response,
delamanid completed
17 Russia 16 F P SS+/C+ (MGIT), Xpert
MTB+, R resistant
XDR-TB: H, R, S, Cm,
Lfx
endTB committee: extensive
resistance to SLDs and severe
clinical presentation (bilateral
lesions)
Z, Cm, Lfx, Pto, PAS, Cs Yes Currently culture negative,
good clinical response,
delamanid ongoing
18 Armenia 16 M P SS+/C+ (MGIT), Xpert
MTB+, R resistant
Pre-XDR (FQ): H, R, Z,
E, Amk, Cm, Pto
endTB committee: extensive
resistance to SLDs and drug
toxicity
Cm, Lfx, Pto, PAS, Cs,
Amx/Clv, Cfz
Yes Currently culture negative,
good clinical response,
delamanid ongoing
19 Swaziland 15 M P SS+/C+ (MGIT), Xpert
MTB+, R resistant
XDR-TB: H, R, E, S,
Cm, Km, Mfx
endTB committee: failure of
previous treatment and
extensive resistance to SLDs
Z, Km, Lfx, Pto, PAS, Cs Yes First culture not yet
available
TB: tuberculosis; SS: sputum smear; C: culture; M: male; F: female; P: pulmonary; EP: extrapulmonary; MGIT: Mycobacteria Growth Indicator Tube (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA); Xpert: Xpert Mycobacterium tuberculosis (MTB)/rifampicin test (Cepheid, Sunnyvale, CA, USA); XDR: extensively drug-resistant; H: isoniazid; R: rifampicin; Z:
pyrazinamide; E: ethambutol; S: streptomycin; Rfb: rifabutin; Amk: amikacin; Cm: capreomycin; Km: kanamycin; Lfx: levofloxacin; Mfx: moxifloxacin; Ofx: ofloxacin; Eto: ethionamide; Pto:
prothionamide; HdH: high-dose isoniazid; SLDs: second-line drugs; PAS: para-aminosalicylic acid; Tzd: terizidone; Amx/Clv: amoxicillin plus clavulanate; Clr: clarithromycin; Cfz:
clofazimine; Lzd: linezolid; Mpm: meropenem; Cs: cycloserine; MDR: multidrug-resistant; FQ: fluoroquinolones; HAIN: GenoType MTBDRplus (Hain Lifescience GmbH, Nehren, Germany).
#: after inclusion in delamanid compassionate use programme, treating clinicians decided to withdraw the request for delamanid for this patient due to adverse effects and poor
treatment adherence; ¶: awaiting import permit from the relevant authorities; +: patient withdrawn from compassionate use programme for programmatic reasons.
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The recent announcement that delamanid is accessible through the Global Drug Facility for USD 1700 per
treatment is an important step forward in increasing international access, avoiding the need for a
compassionate use mechanism. However, countries may still face other barriers, such as lack of
appropriate tools (clinical guidelines, appropriate training and national implementation plans),
pharmacovigilance reporting requirements (which, although essential, are a new challenge for providers
and programmes), and, lastly, budgets to cover the costs of these drugs. All are required to ensure rational
use of delamanid in adult and paediatric patients.
In addition, the lack of inclusion of children in bedaquiline trials to date is not acceptable and contributes
to the current situation of very limited access to this drug among children.
Wider availability of both drugs for children, including those with clinical TB and contact with a known
MDR/XDR-TB source case, is urgently needed, as is the proactive inclusion of children and adolescents in
trials of novel TB drugs [16].
Case-by-case evaluation from independent bodies like the TB Consilium and endTB committee is a
valuable support to clinicians and programmes in the use of the new drugs in children, particularly where
the clinical cases are complex and in the absence of formal guidance for their paediatric use. The use of
these services could contribute to an increase in the appropriate use of new drugs among children and
adolescents in need.
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Variation in policy and practice of
adolescent tuberculosis management in
the WHO European Region
To the Editor:
Tuberculosis (TB) is a major public health concern worldwide. The World Health Organization (WHO)
estimates that 9.6 million people fell ill with TB and 1.5 million people died of TB in 2014. Of an
estimated total of 1 million children with TB, 140000 children died [1]. The risk of progression to TB is
highest for children <5 years of age. There is a comparatively low risk for those 5–10 years of age, after
which the risk of progression to TB increases at the onset of puberty to an adult level of 5–10% [2] as well
as the chance of developing an adult-type TB accompanied by increased infectiousness [3]. However,
adolescents form a particularly vulnerable group with psychosocial challenges distinct from adults and the
usual challenges of transition from paediatric to adult health service provision. Puberty may affect health
behaviour and have a significant impact on therapy compliance [4], requiring specific approaches usually
not provided by paediatric or adult health services [5].
The current guidelines for childhood TB cover children from 0 to 14 years of age but do not specifically
deal with adolescents aged 10–18 years [5, 6]. WHO surveillance guidelines recommend to record and
report two age bands (0–4 years and 5–14 years) [5], and thus specific epidemiological information on
adolescents is lacking. To gain more insight in TB management among adolescents, the WHO European
Regional Task Force on childhood TB conducted a survey among the 53 member states of the WHO
European Region [7]. In January 2015, all national TB programme managers and designated childhood TB
focal points were asked to provide information on the existence and nature of policies and practical
management of adolescents with TB in their country. Responses received by April 30, 2015 were analysed
using Excel 2010 (Microsoft, Redmond, WA, USA). 28 (53%) countries responded to the first part of the
questionnaire on policy and 20 countries also completed the questions on management of adolescents
with TB. The relevant results are summarised in table 1.
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